Education
About Us
Working with TipRanks
Follow Us
Labcorp Holdings Inc. (LH)
NYSE:LH
Earnings Data
Report Date
May 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
4.13Last Year’s EPS
3.84Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call portrays a fundamentally strong and growing business: solid full-year revenue and EPS growth, margin expansion, robust central lab backlog and book-to-bill, continued product launches and AI/automation investments, plus a constructive 2026 guidance. Offsetting risks include a meaningful decline in early development revenue (being actively addressed via streamlining), a one-off Q4 volume hit from a large consumer-genetics client and weather, higher near-term capital spending for a new central lab facility, and ongoing reimbursement/regulatory uncertainty (PAMA). On balance, the positives (organic growth, margin expansion, strong backlog/book-to-bill, innovation and disciplined capital allocation) outweigh the headwinds, though management expects some transitional impacts in ED and incremental capex this year.Company Guidance
Strong Full-Year Revenue and EPS Growth
2025 enterprise revenue grew over 7% year-over-year and adjusted EPS grew 13% for the full year; management noted adjusted EPS growth of ~13% and margins improved by over 50 basis points versus prior year.
Robust Q4 Financial Performance
Q4 2025 revenue was $3.5 billion, up 5.6% YoY (organic +3.8%); adjusted operating income was $488 million (13.9% of revenue) vs $423 million (12.7% prior year); Q4 adjusted EPS was $4.07, up 18% YoY.
Diagnostics Segment Strength
Diagnostics Q4 revenue $2.7 billion, up 5.5% YoY with organic growth of 4.1%; total volume increased 2.2%; price/mix rose 3.3%; Diagnostics adjusted operating income $419 million (15.4% margin), up 150 basis points YoY.
Biopharma / Central Labs Momentum
Central Labs revenue in BLS grew 11.1% in the quarter (7.7% constant currency); BLS segment book-to-bill was strong at 1.16 for the quarter and 1.09 trailing 12 months; backlog ended Q4 at $8.7 billion with ~$2.7 billion expected to convert in 12 months.
Cash Generation and Capital Allocation
Full-year free cash flow was $1.2 billion (up 10% YoY). In Q4 the company invested $258 million in acquisitions, repurchased $225 million of stock and paid $59 million of dividends; share repurchase authorization remaining ~ $800 million.
Strategic M&A and Asset Wins
Completed multiple acquisitions and asset deals in Q4 and subsequent period (Parkview select outreach agreement, Community Health Systems outreach assets, Incyte Diagnostics anatomic pathology assets, and Empire City Labs assets post-quarter), contributing to >$1 billion of revenue growth over the past three years from hospital/regional deals.
Product and Technology Innovation
Launched 130+ new tests in 2025 focused on oncology, women's health, neurology and autoimmune disease; esoteric testing grew double-digits and increased share from 37.5% (Q1 2023) to 41.5% (Q4 2025). Introduced FDA-cleared blood test for Alzheimer's, expanded MRD testing, expanded OnDemand to 200+ biomarkers, and advanced AI/automation (pathology, cytology, microbiology) and a Roche automated mass spectrometry agreement.
2026 Outlook Showing Continued Growth
2026 guidance: enterprise revenue growth 4.7%–6% (midpoint ~5.4%), adjusted EPS $17.65–$18.25 implying ~9% growth at midpoint, free cash flow guidance $1.24B–$1.36B, expected margin expansion across both segments, and LaunchPad savings targeted $100M–$125M annually.
LH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 17, 2026 | $281.92 | $275.98 | -2.11% |
Oct 28, 2025 | $274.24 | $258.35 | -5.79% |
Jul 24, 2025 | $248.57 | $265.62 | +6.86% |
Apr 29, 2025 | $227.16 | $237.87 | +4.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Labcorp Holdings Inc. (LH) report earnings?
Labcorp Holdings Inc. (LH) is schdueled to report earning on May 05, 2026, Before Open (Confirmed).
What is Labcorp Holdings Inc. (LH) earnings time?
Labcorp Holdings Inc. (LH) earnings time is at May 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LH EPS forecast?
LH EPS forecast for the fiscal quarter 2026 (Q1) is 4.13.